PMID- 23179760
OWN - NLM
STAT- MEDLINE
DCOM- 20130228
LR  - 20211021
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 462
IP  - 1
DP  - 2013 Jan
TI  - Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal 
      squamous cell carcinoma.
PG  - 73-81
LID - 10.1007/s00428-012-1340-x [doi]
AB  - The development of laryngeal squamous cell carcinomas (LSCC) is strongly 
      influenced by the host immune system. Indoleamine 2,3-dioxygenase (IDO) can 
      promote and maintain an immunosuppressive microenvironment which can impede the 
      efficacy of anticancer responses. The purpose of the current study is to 
      investigate the prognostic value of intratumoral IDO expression in LSCC. The 
      expression of IDO protein was retrospectively assessed by immunohistochemistry in 
      187 LSCC patients. The potential association of tumor IDO expression with 
      clinical parameters and tumor-infiltrating lymphocytes (TILs) was analyzed 
      separately. Survival curves were estimated by the Kaplan-Meier method, and 
      differences between groups were determined by log-rank test. Multivariate 
      logistic regression analysis was performed to determine the independent factors 
      associated with survival. Based on the evaluation score, 90 carcinomas (48.1 %) 
      were identified with high IDO expression and 97 carcinomas (51.9 %) showed low 
      expression. Tumor IDO expression was not associated with clinical stage, presence 
      of metastases, and other clinicopathological parameters. Also, high IDO 
      expression was not correlated with tumor-infiltrating CD3(+) and CD8(+) TILs. 
      Instead it was positively related with the density of FOXP3(+) Tregs. 
      Furthermore, multivariate analysis identified a significant association of 
      overall survival and disease-free survival with tumor IDO status. IDO high 
      expression represents a significant negative prognostic factor in patients with 
      LSCC. Current results provide further support for using IDO as an 
      immunotherapeutic target in LSCC. The precise role of tumoral IDO in human LSCC 
      remains to be elucidated in the future.
FAU - Ye, Jin
AU  - Ye J
AD  - Department of Otolaryngology, Head and Neck Surgery, The Third Affiliated 
      Hospital of Sun Yat-Sen University, No. 600 Tianhe Street, Guangzhou, Guangdong, 
      510630, China. yejin_sums@yahoo.com.cn
FAU - Liu, Hui
AU  - Liu H
FAU - Hu, Yanming
AU  - Hu Y
FAU - Li, Peng
AU  - Li P
FAU - Zhang, Gehua
AU  - Zhang G
FAU - Li, Yuan
AU  - Li Y
LA  - eng
PT  - Journal Article
DEP - 20121120
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Squamous Cell/diagnosis/*enzymology/mortality/secondary
MH  - China/epidemiology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/*metabolism
MH  - Laryngeal Neoplasms/diagnosis/*enzymology/mortality
MH  - Lymph Nodes/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2012/11/28 06:00
MHDA- 2013/03/01 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/07/12 00:00 [received]
PHST- 2012/11/05 00:00 [accepted]
PHST- 2012/08/28 00:00 [revised]
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2013/03/01 06:00 [medline]
AID - 10.1007/s00428-012-1340-x [doi]
PST - ppublish
SO  - Virchows Arch. 2013 Jan;462(1):73-81. doi: 10.1007/s00428-012-1340-x. Epub 2012 
      Nov 20.